Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Jun 2018
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 13 Jun 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 13 Jun 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 02 Jun 2017 Results (n=15) exploring changes in cerebrospinal fluid circulating tumor cells enumeration in response to treatment presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.